Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group

Bassem I. YamoutInternal Medicine, American University of Beirut, Beirut, LebanonCorrespondence[email protected]

Maurice DahdalehDepartment of Neurology, Arab Medical Centre, Amman, Jordan

Mohammed Ali Al JumahKing Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

Suhail Al-ShammriNeurology Division, Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait

Isa Al SharoqiNeurology Unit, Salamaniya Medical Complex, Manama, Bahrain

Abdel Rahman Al-TahanNeurology Section, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Saeed BohlegaDepartment of Neuroscience, King Faisal Specialist Hospital and Research Center., Riyadh, Saudi Arabia

Dirk DeleuDepartment of Neurology (Medicine), Hamad Medical Corporation, Doha, Qatar

Jihad InshasiDepartment of Neurology, Rashid Hospital, Dubai Health Authority Dubai, United Arab Emirates and Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates

Ahmad KhalifaDepartment of Neurology, Damascus Hospital, Damascus, Syrian Arab Republic

Miklos SzólicsDivision of Neurology, Tawam Hospital in affiliation with Johns Hopkins Medicine, Al Ain, Abu Dhabi Emirate, United Arab Emirates

show all

ABSTRACT

Adherence to therapy is a key issue in chronic illnesses. In addition, several features of multiple sclerosis (MS) and its treatment may increase the likelihood of patient nonadherence and discontinuation of treatment. Nonadherence will obviously compromise the efficacy of disease-modifying drugs in patients with MS. This subject was discussed by a group of local MS specialists from the Middle East. The group debated several key questions about the features and causes of patient nonadherence and its management. Further, they made recommendations for optimizing treatment adherence in this area.

KEYWORDS: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group

Information for

Open access

Opportunities

Help and information

Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature